JPRN-jRCT2080221000
Unknown
Phase 1
An Open-label, Multi-centre, Drug-drug Interaction Study to Assess the Effect of Voglibose (0.2mg Tid) on the Pharmacokinetics, Safety and Tolerability of Single Oral Administration of Dapagliflozin (10mg) in Japanese Patients With Type 2 Diabetes
ConditionsType 2 Diabetes Mellitus
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Type 2 Diabetes Mellitus
- Sponsor
- AstraZeneca
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Already on voglibose treatment with a steady dosage for at least 8 weeks
- •\- Provision of informed consent prior to any study specific procedures
- •\- Diagnosed with type 2 diabetes
Exclusion Criteria
- •\- Having clinically relevant medical history or concurrent disease such as cardiovascular disease, renal disease, retinopathy, hepatic disease and haematological disease.
- •\- The investigator(s) judged that the Subject should not participate in the study according to screening test or medical history.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 3
An Open-label, Single-center, Drug-drug Interaction Study to Assess the Effect of SK-0403 on the Pharmacokinetics, Pharmacodynamics and Safety of Multiple Oral Administration of Metformin in Japanese Patients With Type 2 DiabetesType 2 diabetes mellitusJPRN-jRCT2080221200SANWA KAGAKU KENKYUSHO Co., Ltd.18
Unknown
Phase 3
An Open-label, Single-center, Drug-drug Interaction Study to Assess the Effect of SK-0403 on the Pharmacokinetics, Pharmacodynamics and Safety of Multiple Oral Administration of Miglitol in Japanese Patients With Type 2 DiabetesType 2 diabetes mellitusJPRN-jRCT2080221125SANWA KAGAKU KENKYUSHO Co., Ltd.18
Completed
Not Applicable
An open-label, multi-centre drug-drug interaction trial to investigate the effects of tralokinumab on the pharmacokinetics of selected cytochrome P450 (CYP) substrates in adult subjects with moderate-to-severe atopic dermatitisNL-OMON46290eo Pharma10
Recruiting
Not Applicable
Efficacy and Safety of Dietary Fiber in Patients with Acute Ischemic StrokeAcute ischemic strokeAcute ischemic stroke, enteral nutrition, short-chain fatty acidsD000083242JPRN-jRCTs031230208Kurita Naohide38
Active, not recruiting
Phase 1
A study to evaluate the effect of Levonorgestrel-Emergency Contraception Tablet on Ovulation Inhibition in groups with a BMI that ranges underweight to obeseOvulationMedDRA version: 20.0Level: PTClassification code 10036251Term: Post coital contraceptionSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 20.0Level: LLTClassification code 10033313Term: Ovulation inhibitedSystem Organ Class: 100000004860Therapeutic area: Body processes [G] - Reproductive physiologi cal processes [G08]EUCTR2019-001143-43-GBGedeon Richter Plc.520